

Hodgkin Lymphoma: A Retrospective Clinical and Pathological Analyses with correlation to Treatment Outcome

Thesis

Submitted for partial fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine


Presented by
Nour Sulaiman AlShahawy
M.B, B.Ch.

Under supervision of
Prof. Dr. Mahmoud Mahmoud Elleithy
Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Prof. Dr. Mohamed Yassin Mustafa
Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Dr. Doaa Atef Mohamed
Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

2017



Acknowledgment

First of all, thanks to **Allah** for helping and guiding me in accomplishing this work and for everything else I have.

Praise and gratitude is to ALLAH whom without his aid I would not have accomplished this work.

*I am deeply grateful to **Prof. Dr. Mahmoud Mahmoud Elleithy**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his generous help and supervision.*

*I feel greatly indebted to **Prof. Dr. Mohamed Yassin Mustafa**, Assistant professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his trustful help, sincere guidance and continuous support.*

*As I wish to express my deepest and ultimate gratitude to **Dr. Doaa Atef Mohamed**, Lecturer of Clinical Oncology and Nuclear Medicine, for her endless help providing me with all the encouragement, assistance and support.*

Last no words can express how thankful I am, for my beautiful family, who supported me in all ways and by all means, especially my lovely mother my backbone and wonderful warrior.

Nour Sulaiman AlShahawy

Contents

Introduction	1
Aim of the Study	3
Epidemiology & Etiology	4
Etiological Factors	6
Epstein-Barr virus (EBV)	6
Human immunosuppressant virus (HIV) infection	9
Hodgkin lymphoma and other immune disorders	10
Association with Non-Hodgkin lymphoma	11
Geographic and socioeconomic considerations	11
Familial Hodgkin's disease	12
Pathological Classification	14
Classical Hodgkin Lymphoma	15
Nodular lymphocyte predominant	18
Clinical Presentation & Prognosis	23
Prognostic Factors	29
Prognostic Factors for early Stage HD	30
Prognostic Factors for Advanced Stage Disease	31
Role of PET CT in Hodgkin Lymphoma	33
Treatment of Hodgkin Lymphoma	37
Principles of Chemotherapy	37
Principles of Radiotherapy	39
Treatment of early stage favourable disease	43
Treatment of early stage unfavourable disease	48
Treatment of advanced stage Hodgkin lymphoma	52
Refractory and Relapsed HL	58
Refractory Disease	61
Relapsed Disease	62
Novel Agents	64
Brentuximab vedotin (SGN-39)	65

PD-1/PD-L1 Inhibitors	67
Histone Deacetylase Inhibitors	68
PI3K/Akt/mTOR Pathway	71
Lenalomide	72
Other Chemotherapeutic agent	72
Late Effects & Survivorship	74
Secondary Cancer	74
Cardiovascular disease	75
Hypothyroidism	75
Myelosuppression	75
Pulmonary Toxicity	76
Infertility	76
Follow up	77
Design and Methodology	79
Results	82
Statistical analysis	103
Discussion	120
Summary and Conclusion	139
References	141

LIST OF FIGURES

Figure (1): Percent of cases and 5-year Relative survival by stage at diagnosis.....	5
Figure (2): The role of EBV in the generation of the peculiar phenotype of HRS cells.	8
Figure (3): Classic Reed-Sternberg cell with owl-eye inclusion-like nucleoli.	16
Figure (4): Hodgkin/Reed–Sternberg (HRS) cells may originate from pre-apoptotic germinal centre B cells.....	17
Figure (5): The LP cell: the neoplastic cell in NLPHL, has a multilobate/folded nucleus with smaller basophilic nucleoli giving the cell a “popcorn” appearance (H&E).....	19
Figure (6): Nodular lymphocyte predominant Hodgkin Lymphoma: The background of lymphocytes and paucity of Reed-Sternberg cells make this nonclassic type of HL difficult to distinguish from small cell lymphomas.....	19
Figure (7): The principles for extended field and involved field radiation therapy of the past and for modern involved node and involved site radiation therapy.	42
Figure (8): Involved node radiotherapy in axillary Hodgkin lymphoma.	42
Figure (9): INRT for patient with stage IA inguinal	

Hodgkin lymphoma showing treatment to unilateral right inguinal lymph nodes.....	43
Figure (10): First-line treatment options for early-stage favourable disease classical Hodgkin lymphoma	44
Figure (11): First-line treatment options for early-stage unfavourable disease classical Hodgkin lymphoma.....	48
Figure (12): Treatment of advanced stage Hodgkin lymphoma.....	53
Figure (13): Mechanisms of action of novel targeted drugs.....	64
Figure (14): Histogram of age showing bimodal distribution.....	82
Figure (15): Sex distribution of patients	83
Figure (16): Prevalence of pathological subtypes among patients.....	84
Figure (17): Distribution of stages among patients.....	85
Figure (18): Early versus late disease distribution...	86
Figure (19): Number of cycles of ABVD in Stage I patients.....	89
Figure (20): Response to first line treatment in Stage I patients.....	90
Figure (21): Stage II Nodal Sites distribution	92
Figure (22): Response to first line treatment in Stage II patients	93

Figure (23): Number of chemotherapy cycles in Stage II disease.	93
Figure (24): Response to treatment in Stage III patients.	95
Figure (25): Response to first line treatment in Stage IV patients.	96
Figure (26): Histogram of Overall survival.	98
Figure (28): Relapse after first line chemotherapy	100
Figure (29): Response to first line chemotherapy ..	101
Figure (30): Kaplan Meier Curve of overall survival	103
Figure (31): Kaplan Meier curve of disease free survival.....	104
Figure (32): Kaplan Meier Curve of progression free survival.....	105
Figure (33): The effect of stage on 5 year overall survival.....	108
Figure (34): The relationship between bulky disease and overall survival	109
Figure (35): The relationship between extranodal disease and 5 year OS.....	110
Figure (36): The effect of stage on PFS where 1 is early stage and 2 is advanced stage	116
Figure (37): The effect of bulky disease on PFS where 1 is non bulky disease and 2 is bulky disease.	117

Figure (38): The effect of extranodal disease on PFS
where 1 is nodal disease and 2 is extranodal disease.
..... 118

Figure (39): The effect of total leucocytic count on
PFS where 1 is normal total leucocyte count and 2 is
abnormal total leucocyte count 119

LIST OF TABLES:

Table (1): Modified WHO classification of Hodgkin Lymphoma	14
Table (2): Immunohistochemical Features of Hodgkin Lymphoma. Adopted from Histopathology of Hodgkin's Lymphoma.....	21
Table (3): Clinical Features of Hodgkin Lymphoma.	25
Table (4): Modified Ann Arbor System.....	28
Table (5): Unfavourable prognostic factors according to different groups.....	30
Table (6): Response Criteria for Lymphoma.....	36
Table (7): Chemotherapy Regimens in Hodgkin lymphoma).	39
Table (8): Showing the Mean, median, mode and range of Age, overall survival and progression free survival.....	83
Table (9): Patient's characteristics with regard to the variables.....	87
Table (10): Showing 5 year Survivorship in the number of patients recruited.	97
Table (11): Showing the percentage of patients receiving 2, 4, 6 and 8 cycles of ABVD respectively.	99
Table (12): Showing Number of patients being	

treated with radiotherapy in every stage.	99
Table (13): Showing the number of patients receiving second line chemotherapy and whether they are one regimen or more than one regimen in each stage. ...	102
Table (14): Showing response to second line treatment.	102
Table (15): Overall survival in relation to patient's characteristics	106
Table (16): Cox model for overall survival.....	107
Table (17): Mortality and its relation to patient's characteristics	111
Table (18): Relationship between Complete remission and patient's characteristics.....	112
Table (19): Progression in relation to patient's Characteristics.....	113
Table (20): Progression free survival in relation to patient characteristics	114
Table (21): Cox model for progression free survival.....	115

LIST OF ABBREVIATIONS

AER	Absolute excess risk
AIDS	Acquired Immunodeficiency Disease Syndrome
ASCT	Autologous stem cell transplantation
BEACOPP	Chemotherapy Regimen: Bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, prednisone.
BMB	Bone marrow biopsy
B2M	Beta-2 microglobulin
BV	Brentuximab vedotin
CALBG	Cancer and Leukemia Group B
CAR	Chimeric antigen receptor T cell
CBC	Complete blood Picture
CD	Cluster of differentiation
CHL	Classical Hodgkin lymphoma
ChlVPP/PABIOE	Chlorambucil, vinblastine, procarbazine and prednisone alternating with prednisolone, Adriamycin (doxorubicin), bleomycin, vincristine (Oncovin) and etoposide
CI	Confidence interval
CLL	Chronic lymphocytic leukemia
CR	Complete response
Cru	Unconfirmed Complete Response
CS	Clinical stage
CSS	Cancer specific survival
CT	Computed tomography

DCRDisease control rate

DFS.....Disease free survival

DHAP chemotherapy regimen...Dexamethasone, cytarabine, cisplatin

DORDuration of response

DSS.....Disease specific survival

EBVEpstein Barr Virus

EBVNA1EBV nuclear antigen 1

ECOGEastern Cooperative Oncology Group

ECOG PS.....Eastern Cooperative Oncology Group performance status

EFRTExtended field RT

EORTCEuropean Organisation for Research and Treatment of Cancer

ESHAP chemotherapy regimen... Etoposide, steroid [methylprednisolone], high-dose cytarabine, and cisplatin)

ESRErythrocyte sedimentation rate

Fas-receptorImmunohistochemistry marker; apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 (CD95) or tumor necrosis factor receptor superfamily member 6 (TNFRSF6)

FDG.....18F-fluorodeoxyglucose

FDG PET-CT18F-fluorodeoxyglucose positron-emission
computed tomography

FFPFreedom from progression

FFTFFreedom from treatment failure

FLICE-like inhibitory protein (c- flip)... Protease-dead, procaspase-8-like regulator of death ligand-induced apoptosis

GCGerminal Centre

GDP chemotherapy regimen Gemcitabine, dexamethasone, and cisplatin

GHSG.....German Hodgkin's Lymphoma Study Group

GVD chemotherapy regimen... Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin

GVLGraft versus Lymphoma

HDACHistone deacetylase inhibitors

HDT/ ASCRHigh dose treatment/ Autologous stem cell rescue

HRHazards ratio

HRS.....Hodgkin Reed Stenberg Cells

Hcs.....Hodgkin Cells

HLHodgkin lymphoma

HLAHuman leukocyte antigen

HIV.....Human immunodeficiency virus

HSCTHematopoietic stem cell transplantation

ICE chemotherapy regimen...Ifosfamide, carboplatin, etoposide

IGEV chemotherapy regimen...Ifosfamide, prednisolone, gemcitabine, and vinorelbine

IHC.....Immunohistochemistry

IFRT.....Involved field radiation therapy

INK4A;p16Immunohistochemistry marker; cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1

INRTInvolved node radiation therapy

IPS/IPIInternational Prognostic Score, international prognostic index

ISRT.....Involved Site radiation therapy

LDHLactate dehydrogenase

LDHL.....Lymphocyte depleted Hodgkin lymphoma

LRCHL.....Lymphocyte rich Hodgkin lymphoma

LMP1Latent membrane protein 1

LMP2Latent membrane protein 2

LOPP.....Lomustine (CCNU), vincristine, procarbazine and prednisolone.

LOPP/EVAP.....Lomustine (CCNU), vincristine, procarbazine and prednisolone alternating with etoposide, vinblastine, Adriamycin and prednisone

MCHL.....Mixed cellularity Hodgkin lymphoma

MGCD0103Mocetinostat

Mini BEAM chemotherapy regimen... Carmustine, etoposide, cytarabine, melphalan.

MRI.....Magnetic resonance imaging

MMAEMonomethyl auristatin E

MOPP chemotherapy regimen... Mechlo-rethamine, Vincristine, procarbazine, prednisone

MTOR.....Mammalian target of rapamycin inhibition

MVPP.....Mustine, vinblastine, procarbazine, prednisolone

NCICNational Cancer Institute of Canada

NCCN.....National Comprehensive Cancer Network

NfκB.....Nuclear factor κB

NSCHLNodular sclerosis Hodgkin lymphoma

OROdds ratio

ORROverall response rate

OSOverall survival

p53.....Tumour Suppressor 53; phosphoprotein p53

Pax-5/B cell-specific activator protein... Immunohistochemistry marker; member of the paired box (PAX) family of transcription factors

PET-CT Positron-emission computed tomography

PFS Progression free survival

PD Progressive disease

PD-1 Programmed death-1

PD-L1 Programmed death-1 ligands

PD-L2 Programmed death-2 ligands

PI3K/Akt/mTOR .. Intracellular signaling pathway important in regulating the cell cycle

PML Progressive multifocal leukencephalopathy

PR Partial response

PS Performance Status

PWHA Person(s) with HIV/AIDS

Rb Retinoblastoma tumour suppressor gene

RECIST Response evaluation criteria in solid tumours

Rel/Ref HL Relapsed/refractory hodgkin lymphoma

RT Radiation therapy

SGN35 Brentuximab Vedotin

SPD Sum of products of diameter

Stanford V chemotherapy regimen... Doxorubicin, vinblastine, mechlo-rethamine vincristine, bleomycin, etoposide, prednisone

STNI Subtotal nodal irradiation

TARC Thymus and activation-related chemokine

Th2 cells T helper2 cells

THRLBCL T-cell/histiocyte-rich large B-cell lymphoma

TSH Thyroid-stimulating hormone levels